# Chemoradiotherapy in Unresectable Esophageal Cancer

> **NCT04278287** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 105 (estimated)

## Conditions studied

- Esophageal Cancer
- Chemoradiotherapy
- Albumin-bound Paxlitaxel
- Unresectable Malignant Neoplasm

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04278287
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-01
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278287, "Chemoradiotherapy in Unresectable Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04278287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*